ClearPoint Neuro, Inc. (CLPT)
Nasdaq · Healthcare · Medical Devices
$11.52+5.74%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $351M
- 52-week range
- $8.27 – $30.10
- 52-week change
- −58.70%
- EPS (trailing)
- −$1.18
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $37.0M (+17.78%)
- Net income
- −$25.5M
- Operating margin
- −65.4%
- Diluted EPS
- −$0.90
- Free cash flow
- −$24.4M
From the company’s annual report on SEC EDGAR.
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting.
Headquarters: Solana Beach, United States · 160 employees · clearpointneuro.com